ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Circulating Cell-Free DNA as an Integrative Biomarker in Breast Cancer: Correlation with Molecular Subtypes, Mutation Status, and Treatment Response
Provisionally accepted
Ranjana Solanki
Dr Ashmeet Kaur*
Ravindra Gothwal
Kamal Kishore Lakhera
Bhuvanesh Sukhlal Kalal
Urvashi Vijay- Sms Medical College, Jaipur, Rajasthan, India, Jaipur, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Cell-free DNA (cfDNA) is an emerging non-invasive biomarker in oncology. While its diagnostic and prognostic roles in breast cancer are established, limited studies have examined cfDNA dynamics in relation to molecular subtypes and mutation profiles, particularly in underrepresented populations. Objectives: To assess the diagnostic and predictive utility of cfDNA in breast cancer by analyzing its association with molecular subtypes, TP53 and PIK3CA mutations, and treatment response across dual timepoints. Methods: Fifty histologically confirmed breast cancer patients and 20 age-matched healthy controls were enrolled. Baseline and follow-up cfDNA levels were quantified in 32 paired cases. cfDNA dynamics (ΔcfDNA) were analyzed by subtype and mutation status. Diagnostic and predictive performance was evaluated using ROC (Receiver operating characteristic) and Precision–Recall (PR) curve analyses. Mutation distribution and subtype frequencies were compared with global and regional datasets. Results: Baseline cfDNA levels were significantly elevated in breast cancer patients compared to controls (p < 0.001), with highest levels in TNBC (Triple-negative breast cancer) and HER2-enriched subtypes and lowest in Luminal A. Follow-up cfDNA remained persistently elevated in aggressive subtypes and TP53-mutated cases, suggesting molecular residual disease. ΔcfDNA trends varied, with TP53-mutated TNBC showing the highest increases. PIK3CA mutations were observed in 36% of cases, predominantly E545K (28%), while H1047R was rare (2%). TP53 mutations were detected in 10%. PR analysis showed moderate predictive value for TP53 (Average Precision = 0.72) and PIK3CA (Average Precision = 0.71). A cfDNA threshold of 137 ng/mL achieved 91% sensitivity and 92% specificity (Area Under the Curve = 0.97). Conclusion: cfDNA levels reflect tumor burden, subtype biology, and mutation status, offering real-time, non-invasive insight into disease dynamics. The high E545K and rare H1047R frequencies suggest underexplored, population-specific genomic patterns. cfDNA trends across subtypes range from persistent elevation in TNBC to decline in Luminal A, suggesting its potential role in treatment monitoring. These findings underscore cfDNA's relevance to evolving precision oncology frameworks, particularly in biopsy-limited and resource-constrained settings.
Keywords: breast cancer, cell-free DNA, cfDNA dynamics, liquid biopsy, Molecular subtypes, PIK3CA mutation, precision oncology, TP53 mutation
Received: 01 Nov 2025; Accepted: 16 Jan 2026.
Copyright: © 2026 Solanki, Kaur, Gothwal, Lakhera, Kalal and Vijay. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr Ashmeet Kaur
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.